References in periodicals archive ?
Recombinant human interleukin-12 induces lesion regression in some cutaneous T-cell lymphomas, reported Dr.
Lymphocyte activation in cutaneous T-cell lymphoma.
Our BioTherapeutics business segment is developing SGX301 as a first-in-class photo-dynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma, proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation including pediatric Crohn's disease (SGX203) and acute radiation enteritis (SGX201), and our novel innate defense regulator technology (SGX942) for the treatment of oral mucositis.
Cutaneous T-cell lymphoma is a rare and life-threatening form of Non-Hodgkin's lymphoma that happens most often in people older than 55.
The randomized, double-blind, controlled clinical study is the largest ever undertaken involving patients with cutaneous T-cell lymphoma.
HuMax-CD4 is a human monoclonal antibody currently in Phase III development for cutaneous T-cell lymphoma (CTCL) and in Phase II for non-cutaneous T-cell lymphoma.
OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the formation of a Medical Advisory Board (MAB) to provide medical/clinical strategic guidance to the Company as it advances the Phase 3 clinical development of SGX301 (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare class of non-Hodgkin's lymphoma (NHL).
Within the head and neck, cutaneous T-cell lymphoma has been found in the hypopharynx, larynx, oropharynx, nasopharynx, oral cavity, maxillary sinus, mastoid, external and middle ear, and the cheek.
An out-of-body blood treatment cancontrol cutaneous T-cell lymphoma (CTCL), a potentially deadly cancer, according to an international group of researchers.
02% to pharmacy-compounded mechlorethamine ointment for the treatment of early stage mycosis fungoides (MF), the most common form of cutaneous T-cell lymphoma (CTCL), have been published in JAMA Dermatology (formerly Archives of Dermatology).
Chidamide, an oral, selective histone deacetylase (HDAC) inhibitor, is currently being evaluated in Phase II trials by Chipscreen Biosciences in Peripheral T-Cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL) and Non-Small Cell Lung Cancer patients (NSCLC).
Prior to the financing, Ceptaris received a Complete Response Letter from the Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for mechlorethamine gel for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL).
the developer of ImmunoPulse, is focusing on advanced-stage skin cancers: metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma.
a year-long global initiative marking the 25-year anniversary of the introduction of ECP for the treatment of cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin's lymphoma.
OncoSec Will Evaluate ElectroImmunotherapy Against Melanoma, Merkel Cell Carcinoma, and Cutaneous T-Cell Lymphoma